Site Search

... patients. Beginning in the new year, Act 39 of 2024 will make it so that all patients who can benefit and are insured through a state-regulated health plan will receive coverage for biomarker testing, a game changer in the fight against cancer and an essential step in accessing precision medicine treatments. Pennsylvanians also secured a victory for access to care through Act 42 of 2024, the newly enacted legislation that includes telemedicine as a covered benefit in the Commonwealth. “This legislative ... so that a person’s economic status does not determine whether or not they have the ability to detect and survive cancer. “Soaring health care costs have made it so that patients are forced to take on medical debt and suffer through its cascading effects in order to receive ...

... of Senate Bill 954 / House Bill 1754. This legislation aims to equip countless Pennsylvanians who have received a cancer diagnosis and their health care providers with critical information about their disease and how to best fight it.  “Despite the benefits of biomarker testing in improving patient outcomes and quality of life, health insurance coverage has not kept pace with innovations, coming up short in enabling residents to receive standard of care. Senators Devlin ...

... and partners are working together to make sure more Nevadans can benefit from this important testing.   What is Biomarker Testing? In cancer care, biomarkers are often used to help determine the best treatment for a patient . A “ biomarker ” is a sign of a normal biological process, ... that have been excluded, including communities of color, individuals with lower socioeconomic status, rural communities, and those receiving care in non-academic medical centers are less likely to receive biomarker testing. Improving coverage for and access to biomarker testing across insurance types is key to reducing health disparities. Without action to expand coverage and access to biomarker testing, advances in precision medicine could increase existing ...

... Despite its benefits, access to biomarker testing has not kept pace with the rate of innovation due in part to lack of coverage by private health insurance and Medicaid for needed testing. Senate Bill 2201 aims to enable more Rhode Islanders to benefit from biomarker testing, a ... Cancer Action Network (ACS CAN) in Rhode Island: "Biomarker testing and precision medicine are helping extend and improve lives by tailoring care and treatment to a person’s individual condition. Over the past many months, we have heard countless stories of the difficulties a patient ... and the Rhode Island Senate for approving this legislation. We urge the House to follow suit and also take this critical step towards reducing health inequities and improving cancer outcomes." For more information on precision medicine, cancer biomarkers, current barriers to biomarker ...